UBS Group Upgrades Qiagen (NYSE:QGEN) to “Hold”

Qiagen (NYSE:QGEN) was upgraded by equities researchers at UBS Group to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

Other equities research analysts also recently issued reports about the stock. Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the company a “hold” rating in a research note on Tuesday, July 14th. Stifel Nicolaus set a $40.00 price objective on Qiagen in a research note on Friday, August 7th. Weiss Ratings raised Qiagen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 17th. JPMorgan Chase & Co. raised their price objective on Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Kepler Capital Markets set a $38.60 target price on Qiagen and gave the stock a “hold” rating in a research note on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $43.51.

Qiagen Price Performance

Shares of QGEN opened at $42.39 on Wednesday. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The company’s fifty day simple moving average is $42.20 and its 200 day simple moving average is $40.18. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The company has a market cap of $8.74 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 4.20 and a beta of 0.63.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, research analysts forecast that Qiagen will post 2.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Banque Cantonale Vaudoise lifted its position in Qiagen by 1.8% during the fourth quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock worth $747,000 after acquiring an additional 290 shares during the last quarter. Commerce Bank increased its stake in shares of Qiagen by 4.9% during the fourth quarter. Commerce Bank now owns 6,725 shares of the company’s stock worth $302,000 after purchasing an additional 314 shares during the period. Allworth Financial LP lifted its holdings in Qiagen by 20.8% during the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock worth $72,000 after purchasing an additional 317 shares during the last quarter. Truist Financial Corp lifted its holdings in Qiagen by 4.1% during the 4th quarter. Truist Financial Corp now owns 8,421 shares of the company’s stock worth $379,000 after purchasing an additional 331 shares during the last quarter. Finally, Private Advisor Group LLC lifted its holdings in Qiagen by 7.1% during the 3rd quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock worth $256,000 after purchasing an additional 378 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.